Please login to the form below
UCB’s Mark Bodmer elected to BIA board
Will hold the position for a three-year fixed term
UCB's Mark Bodmer has been elected to the board of UK trade body the BioIndustry Association (BIA).
Bodmer is VP, NewMedicines Therapeutics at UCB, having joined the company in 2012 as head of immunology.
As a board member of the BIA Bodmer will play a role in shaping the policy environment of the UK biotech industry. He will hold the role for three years, starting in January 2015.
Prior to joining UCB Bodmer served as senior VP of immunoinflammation, medicines discovery and development at GlaxoSmithKline.
His background also includes CEO appointments at three start-ups from 1996 to 2007: Hexagen, Lorantis and Biotica.
Featured jobs
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
- Experienced / Senior Medical Writer - MedComms - Cardiff - Wales
-
Excellent Salary and Benefits on offer
- Scientific Director - Medical Communications Agency - New York
-
Excellent Remuneration Package
- Graduate / Entry Level Opportunities – Medical Communications – ...
-
Highly Competitive Remuneration Package
- Senior Medical Writer – Leading Medical Communications Agency – ...
-
Highly Competitive Remuneration Package
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
-
Senior Medical Writer
-
Salary TBC
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
- Scientific Director - Medical Education - Cheshire & London ...
-
Excellent Remuneration Package
- Senior / Principal Medical Writer – Medical Education - UK &...
-
Excellent Salary and Benefits on offer
-
Account Director, Medical Education
-
Salary TBC
Subscribe to our email news alerts
- AstraZeneca’s Calquence impresses in previously untreated CLL
- Novartis highlights emerging assets and late-stage pipeline at R&D day
- Biogen defends aducanumab filing plan amid scepticism
- Armed with new data, BMS plans filings for Celgene CAR-T liso-cel
- Sanofi narrows focus, shedding diabetes and cardiovascular research
- PMEA 2019 Winners Gallery - PMEA
- Sanofi narrows focus, shedding diabetes and cardiovascular research
- Correvio crumbles as FDA panel rejects AFib drug
- BMS’ oral maintenance therapy boosts survival in AML patients
- Sanofi’s sutimlimab set for filing in rare autoimmune anaemia next year
- Pharma Brand Planners' Blog (Part 7)
- Regeneron reveals first data for bispecific antibody in multiple myeloma
PMHub
Purple Agency
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....
Latest intelligence
- The 2019 CPhI Pharma Index Report
- Examining this year’s industry performance...
- Five key trends in precision and personalised healthcare
- Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
- OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
- Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Quick links
Infographics
